Influenza Hemagglutinin (HA) Peptide: Precision in Protein Tagging and Purification

Principle, Setup, and the Role of HA Tag Peptide

The Influenza Hemagglutinin (HA) Peptide, a synthetic nine-amino acid sequence (YPYDVPDYA), is a foundational tool in molecular biology for epitope tagging of recombinant proteins. As a highly purified (>98%) molecule, it enables researchers to reliably detect, purify, and study HA-tagged fusion proteins through its high-affinity, competitive binding to anti-HA antibodies (source: product_spec). The HA tag peptide is widely adopted for immunoprecipitation, protein purification, and interaction assays, offering unmatched specificity and minimal cross-reactivity in complex biological samples.

In typical applications, the HA epitope tag is genetically fused to a protein of interest. Detection and isolation are then achieved using anti-HA antibodies or beads, with the Influenza Hemagglutinin (HA) Peptide functioning as a competitive elution reagent to release the bound HA-tagged protein under gentle, non-denaturing conditions. This approach is particularly valuable for sensitive downstream analyses such as mass spectrometry or enzyme assays, where retention of native protein structure and function is essential (source: paper).

Step-by-Step Workflow Enhancements: Immunoprecipitation and Elution

1. Sample Preparation: Express HA-tagged protein in suitable cells and lyse under non-denaturing conditions to preserve protein-protein interactions.
2. Binding: Incubate lysate with magnetic or agarose anti-HA antibody beads, allowing selective capture via the HA tag sequence.
3. Washing: Wash beads extensively to remove non-specifically bound proteins, optimizing stringency to balance yield and purity.
4. Competitive Elution: Add Influenza Hemagglutinin (HA) Peptide at the recommended concentration (typically 1 mg/mL) in PBS or TBS. Incubate 30–60 minutes at 4°C with gentle agitation to competitively displace HA-tagged proteins from antibody binding sites (source: paper).
5. Collection: Separate the supernatant, containing the eluted HA-tagged protein, for analysis by SDS-PAGE, Western blot, or proteomics.

This workflow allows gentle, antibody-mediated purification that preserves the conformation and biological activity of the protein complex.

Protocol Parameters

• immunoprecipitation with Anti-HA antibody | 20–40 μL bead slurry per 1 mg lysate protein | protein-protein interaction studies | Ensures sufficient capture capacity without antibody excess | paper
• HA tag peptide elution | 1 mg/mL in PBS or TBS | competitive binding to Anti-HA antibody | Provides effective displacement of HA-tagged proteins in <30–60 min at 4°C | product_spec
• HA peptide stock solution | 55.1 mg/mL in DMSO, 100.4 mg/mL in ethanol, 46.2 mg/mL in water | stock storage and dilution | Maximizes solubility and long-term stability; avoid repeated freeze-thaw cycles | product_spec

Advanced Applications and Comparative Advantages

The HA tag peptide’s compact size and defined sequence make it an ideal epitope tag for protein detection in multiplexed assays, minimizing the risk of interfering with protein folding or function (source: paper). Its highly specific, reversible binding to anti-HA antibodies enables the isolation of intact protein complexes for functional studies.

Comparative Insights: Compared to larger tags (e.g., FLAG, GST), the HA tag exhibits lower immunogenicity and less steric hindrance, supporting applications in quantitative proteomics and enzyme activity assays where native conformation is critical. Direct comparisons have shown that the HA peptide’s competitive elution is more gentle and yields higher recovery rates for sensitive complexes than traditional harsh elution buffers (source: paper).

In cancer research, as demonstrated by the reference study on IDH1-R132H autopalmitoylation, HA-tagged constructs enable detailed mapping of post-translational modifications and protein-protein interactions—critical for understanding mechanisms of oncogenic transformation and metabolic reprogramming (source: paper).

Key Innovation from the Reference Study

The landmark study, “Autopalmitoylation of IDH1-R132H regulates its neomorphic activity in cancer cells” (reference), leveraged HA-tagged IDH1 constructs to dissect the role of post-translational palmitoylation in enzyme activity and cancer cell metabolism. By employing immunoprecipitation with anti-HA antibody and competitive HA peptide elution, the researchers efficiently isolated wild-type and mutant IDH1 proteins for downstream chemoproteomic profiling. This strategy preserved native protein-protein and protein-lipid interactions, enabling the discovery of a unique autopalmitoylation event at C269, which modulates oncogenic activity and represents a new druggable vulnerability in IDH1-mutant cancers.

Practically, this underscores the value of the HA tag peptide as a gentle, highly specific reagent for capturing dynamic protein modifications—a critical requirement for interrogating subtle regulatory mechanisms in cancer signaling and metabolism.

Interlinking and Literature Context

• “Influenza Hemagglutinin (HA) Peptide: Precision Tag for P...” provides a detailed breakdown of the HA peptide’s mechanism as an epitope tag and its validated solubility/stability, complementing the data-driven protocol enhancements discussed here.
• “Influenza Hemagglutinin (HA) Peptide: Revolutionizing Epitope Tagging in Cancer Research” extends the conversation, highlighting the peptide’s competitive edge in innovative oncology applications, such as those exemplified by the reference study.
• “Influenza Hemagglutinin (HA) Peptide (SKU A6004): Reliable Workflows” contrasts common troubleshooting scenarios and offers evidence-based recommendations for maximizing reproducibility—directly relevant for users seeking protocol optimization.

Troubleshooting and Optimization Tips

• Low Elution Efficiency: Ensure the HA peptide is freshly prepared and fully dissolved at the correct concentration. Perform elution at 4°C with gentle mixing for 30–60 minutes to maximize competitive binding (source: product_spec).
• Background Contamination: Increase washing stringency by using higher salt buffers or additional wash steps. Verify antibody and bead quality; degraded or overloaded reagents may nonspecifically retain proteins.
• Protein Degradation: Supplement buffers with protease inhibitors and keep samples on ice throughout the workflow. Avoid unnecessary freeze-thaw cycles of both peptide and protein solutions.
• Loss of Activity in Peptide Solutions: Store lyophilized peptide desiccated at -20°C. Prepare aliquots of stock solutions and avoid prolonged storage at room temperature, as repeated freeze-thaw cycles can compromise integrity (source: product_spec).

Why this Cross-Domain Matters, Maturity, and Limitations

The translation of HA tag peptide workflows from classical protein purification to advanced cancer research, as exemplified in the reference study, illustrates the peptide’s flexibility and maturity in supporting multi-domain biological discovery. Its use in chemoproteomic profiling of post-translational modifications demonstrates readiness for cutting-edge applications. However, limitations include potential interference in proteins with endogenous HA-like sequences, and the need for robust controls to distinguish true interactors from background.

Future Outlook

As molecular biology and proteomics advance, the Influenza Hemagglutinin (HA) Peptide will remain an essential reagent for dissecting complex protein interactions and modifications. Its role in enabling non-destructive purification is especially valuable for the study of dynamic signaling events and metabolic pathways, as seen in the IDH1-R132H cancer model (reference). Ongoing improvements in antibody and tag design, along with the integration of quantitative mass spectrometry, will further expand the utility of this classic epitope tag.

For researchers seeking high-purity, reliable HA tag peptide solutions, APExBIO's Influenza Hemagglutinin (HA) Peptide (SKU A6004) represents a trusted standard in the field, validated across diverse platforms and experimental designs.